KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
161 hedge funds and large institutions have $1.08B invested in KalVista Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 53 increasing their positions, 49 reducing their positions, and 20 closing their positions.
2,733% more call options, than puts
Call options by funds: $6.69M | Put options by funds: $236K
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
85% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 20
51% more capital invested
Capital invested by funds: $714M → $1.08B (+$367M)
16.4% more ownership
Funds ownership: 116.03% → 132.43% (+16%)
11% more funds holding
Funds holding: 145 → 161 (+16)
8% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 49
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$30.2M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$16M |
| 3 |
VPC
Vestal Point Capital
New York
|
+$15.1M |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$14.1M |
| 5 |
Millennium Management
New York
|
+$10.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$12.8M |
| 2 |
SCM
Sio Capital Management
New York
|
-$8.33M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$6.2M |
| 4 |
Capital World Investors
Los Angeles,
California
|
-$4.89M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$4.52M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WAM
176
Wolverine Asset Management
Chicago,
Illinois
| – | -$56.8K | -4,662 | Closed |
|
177
Zurich Cantonal Bank
Zurich,
Switzerland
| – | -$60.2K | -4,545 | Closed |
|
178
CIBC Private Wealth Group
Atlanta,
Georgia
| – | -$1.95K | -160 | Closed |
|
|
CA
179
CoreCap Advisors
Southfield,
Michigan
| – | -$280 | -23 | Closed |
|
|
IA
180
IFP Advisors
Tampa,
Florida
| – | -$61 | -5 | Closed |
|
KALV Hedge Fund Activity: Q4 2025 in Review
161 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q4 2025, worth a combined $1.08B — up 51% from $714M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new KALV positions and 20 closed out — a net gain of 17 holders — while 53 added to existing stakes and 49 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $30.2M. The largest seller was Goldman Sachs, cutting an estimated $12.8M.
- 161 institutional investors held KalVista Pharmaceuticals (KALV) as of Q4 2025, up from 145 in Q3 2025.
- Funds reported $1.08B of KalVista Pharmaceuticals stock for Q4 2025, up 51% quarter-over-quarter.
- 37 funds opened new KalVista Pharmaceuticals positions in Q4 2025 and 20 closed out, a net change of +17 holders.
- The largest KalVista Pharmaceuticals buyer in Q4 2025 was Point72 Asset Management, an estimated $30.2M added.
- The largest KalVista Pharmaceuticals seller in Q4 2025 was Goldman Sachs, an estimated $12.8M sold.
Based on aggregated 13F filings for Q4 2025.